Luye Pharma’s Dual TAAR1/5-HT2CR Agonist LY03020 Approved for Clinical Trials in the U.S.

You are leaving the site

You are now leaving the Luye Pharma Ltd website to go to an external website over which Luye Pharma has no control and to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website. Click OK to proceed.